RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function After Heart Attack In Mice
7/15/2014 7:32:01 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that a new paper entitled, Thymosin ß4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. “The present study shows for the first time that 1) Tß4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of Tß4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, Tß4 could potentially be a therapeutic candidate for patients with acute MI,” according to the study’s authors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by